Exelixis | Ventes



Sales Changement Date
Acadia Pharmaceuticals USD 259.6M 9.2M 2024-12
Agios Pharmaceuticals USD 10.73M 1.77M 2024-12
Amgen USD 9.09B 583M 2024-12
AstraZeneca USD 14.89B 1.32B 2024-12
Bayer EUR 11.73B 1.76B 2024-12
BioMarin Pharmaceutical USD 747.31M 1.57M 2024-12
Bristol-Myers Squibb USD 12.34B 450M 2024-12
Cytokinetics USD 16.93M 16.46M 2024-12
Eisai JPY 216.14B 20.15B 2024-12
Eli Lilly USD 13.53B 2.09B 2024-12
Exelixis USD 566.76M 27.21M 2024-12
Genmab DKK 64.41B 58.87B 2024-12
Glaxosmithkline GBP 8.12B 105M 2024-12
Incyte USD 1.18B 40.83M 2024-12
Ionis Pharmaceuticals USD 226.58M 92.76M 2024-12
MacroGenics USD 110.71M 99.91M 2024-09
Merck USD 15.62B 1.03B 2024-12
Moderna USD 966M 896M 2024-12
Neurocrine Biosciences USD 627.7M 5.6M 2024-12
Novartis USD 13.15B 330M 2024-12
Pfizer USD 17.76B 61M 2024-12
Sanofi EUR 11.26B 3.5B 2024-12
Takeda JPY 1.14T 40B 2024-12
Ultragenyx Pharmaceutical USD 164.88M 25.38M 2024-12
Xencor USD 70.02M 59.31M 2024-12



Exelixis Ventes - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Mar 2025.